PSG president Al-Khelaifi charged in French corporate abuse of power probe: source
French judicial authorities have charged the president of Paris Saint-Germain football club, Nasser Al-Khelaifi, with complicity in abuse of power concerning shareholder voting at a company, a source close to the case said Thursday.
Al-Khelaifi was charged on February 5 with complicity in the alleged buying of a vote and harming of freedom to vote over a switch in the voting of a Qatari investment fund on the board of the Lagardere Group in 2018, a judicial source added, with both sources asking not to be named.
The PSG chief, who has led the record 12-times French Ligue 1 champions since its 2011 takeover by Qatar Sports Investments with the dream of making the team Europe's best, has faced several legal cases in recent years but always denied any wrongdoing.
"This file has absolutely and emphatically nothing to do with Nasser Al-Khelaifi, but as usual he will get dragged through a completely spurious process as a famous name, who is apparently responsible for anything and everything, until everything quietly disappears without any grounds whatsoever in a few years," said a source close to the Qatari, also asking not to be named.
Lagardere Group chief Arnaud Lagardere is suspected of having fraudulently used some 125 million euros ($129 million at today's rates) of funds from the group for several years to fund his personal expenses.
The case against Al-Khelaifi, who is known in France as "NAK", concerns a time in 2018 when there was a power struggle on the board between billionaire right-wing tycoon Vincent Bollore, who was allied to the Amber Capital investment fund, and France's richest man Bernard Arnault the boss of the LVMH luxury goods firm who supported Arnaud Lagardere.
On April 24, 2018, Qatar Holding LLC, a subsidiary of the sovereign wealth fund Qatar Investment Authority (QIA) and the main shareholder of Lagardere Group, had positioned itself in favour of the resolutions of Amber Capital.
Arnaud Lagardere and his aides are accused of calling their contacts, including Al-Khelaifi in his capacity as a director of the QIA.
Five days after the first vote, the QIA changed its position and voted in favour of the resolutions put forward by Arnaud Lagardere.
The Lagardere Group was bought after a bitter battle at the end of November 2023 by media and publishing giant Vivendi, controlled by the family of Bollore.
A previous indictment against Al-Khelaifi for alleged corruption over Qatar's bids for the 2017 and 2019 World Athletics Championships was definitively annulled in mid-February 2023 by France's Court of Cassation, which ruled that the French justice system was incompetent to prosecute him.
Parisian investigating magistrates are also probing Al-Khelaifi over accusations of the alleged kidnapping and sequestration in Qatar of Franco-Algerian lobbyist Tayeb Benabderrahmane.
Al-Khelaifi denies the accusations and has himself filed a complaint.
gd-sjw/ah/ea
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025 Opening of AAC targeted for Q4 2025 at the latest Multiple near-term value catalysts expected over next 12 months PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study. Clear Path Forward for LUMEVOQ® AAC Program in France Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025. In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest. "In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment." Financing Strategy to Support Regulatory Milestones GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones. "We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities. " Advancing Core Marketing Authorization Strategy In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities. Multiple Value Catalysts GenSight anticipates a number of significant value-creating events in 2025-2026: Q3 2025: Clinical trial application for focused dose-ranging study Q4 2025: Completion of manufacturing tech transfer Q4 2025: Opening of the AAC program Q2 2026: Completion of Phase III trial preparations Early H2 2026: Initiation of global Phase III clinical trial Early H2 2026: pre-submission meeting with MHRA Financial Position The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025. The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ®. As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares. Risk factors Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website ( and/or AMF ( The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release. View source version on Contacts GenSight Biologics Chief Financial Officer Jan Eryk Umiastowski jeumiastowski@
Yahoo
4 hours ago
- Yahoo
Man says he's the sole survivor of the Air India plane crash
A senior Indian police official told the country's national news agency ANI on Thursday that one person — a man who was in seat 11A on the doomed Air India flight to London that crashed soon after takeoff in the city of Ahmedabad — survived the catastrophe. Indian media outlets spoke with a man in a local hospital who said he was U.K. citizen Vishwash Kumar Ramesh, the person who had been listed in that seat on flight AI171, according to the flight manifest shared by Indian authorities. Ahmedabad Police Commissioner GS Malik, who initially told ANI there were no known survivors from the Boeing 787-8 Dreamliner that crashed into the city, was later quoted by the same news agency as saying "the police found one survivor in seat 11A." He said the person was "in the hospital and is under treatment." "Yes, one survivor is confirmed," said Dhananjay Dwivedi, principal secretary of the Gujarat state health department, according to the French news agency AFP, without identifying the person. Dr. Dhaval Gameti at Ahmedabad's Civil Hospital told The Associated Press that he had examined Ramesh and that while the crash survivor "was disoriented with multiple injuries all over his body... he seems to be out of danger." Gameti told the AP that 186 bodies of passengers from the plane had been brought to the Civil Hospital. Indian media outlets that spoke with Ramesh in the hospital said he had a ticket for the ill-fated flight showing his name and the 11a seat assignment. "Thirty seconds after take-off, there was a loud noise and then the plane crashed. It all happened so quickly," the Hindustan Times quoted Ramesh as saying. The newspaper said he reported suffering "impact injuries" to his chest, face and feet. Video of the crash shows the plane flying low over buildings before dropping out of sight, followed by a massive explosion that sends a giant fireball into the air. Video shows Air India plane crashing in Ahmedabad Air India plane crashes shortly after takeoff, carrying more than 240 people An accused woman skips her pedicure, kills her ex-husband
Yahoo
4 hours ago
- Yahoo
Opinion - A federal solution: The United States of Palestine
As French President Emmanuel Macron tries to revive the same solution that has failed time and time again, the decades-long Israeli-Palestinian conflict continues. With with no lasting solution in sight, it may be time to revisit a concept both deeply historical and radically pragmatic: the idea that Jordan — long tied to the Palestinian people by geography, identity, governance and religion — should take the lead in shaping a new federal solution for Palestinian self-determination. Few remember today that Jordan was, and in many ways still is, part of historic Palestine. Before the 1921 creation of Transjordan under British supervision, the territory we now call Jordan was understood as part of the larger Palestinian entity — the land between the Mediterranean and the Iraqi desert. Though carved out and handed to a Hashemite emir from the Saudi Hejaz, Jordan has always remained tethered to the Palestinian cause, demographically and spiritually. Today, more than 70 percent of Jordan's population is of Palestinian origin. These Jordanian-Palestinians see themselves not as outsiders but as integrated citizens of the Hashemite state. Their presence has not weakened Jordan's identity — it has enriched it. From Nablus merchants to Jerusalem-born educators, the Palestinian community in Jordan is a cornerstone of the kingdom's civic and economic life. Jordan also has a unique religious and political legitimacy in the region. From 1948 to 1967, it ruled the West Bank, including East Jerusalem, and continues to serve as custodian of the Muslim holy sites there, by international agreement. No other government — not the Palestinian Authority, nor Hamas, nor any regional actor — holds that trust. Unlike the divided and often dysfunctional Palestinian political bodies in Gaza and the West Bank, the Hashemite Kingdom has maintained 100 years of strong, stable governance. It has proven its ability to rule justly, suppress extremism and maintain strategic alignment with Western interests. Amman is a loyal U.S. and NATO partner. It has withstood the storms of Arab nationalism, Islamist extremism, regional war and refugee crises — all while keeping its institutions intact and its society relatively moderate and open. In contrast, every attempt at Palestinian self-rule — from the Palestine Liberation Organization's early years through the current Hamas-Fatah split — has ended in disappointment. Palestinian leadership has, at various times, aligned with morally and strategically disastrous actors: the Nazis during World War II, the Soviet bloc during the Cold War, and Saddam Hussein in the 1990s. Internal corruption, repression and a reckless embrace of violence have robbed generations of Palestinians of the chance to live in peace and dignity. It is time to imagine something better: a federal model in which Jordan assumes sovereign oversight of the United States of Palestine. Under this model, Jordan would recognize and integrate several Palestinian states or provinces into a federated structure. Inside current Jordanian borders, three to four states would be formed, each with local state control and democratic representation. The Palestinian-ruled areas in the West Bank would become another state. Gaza, currently caught between Hamas and the Israeli Defence Forces, would form yet another. All of these would retain autonomy over education, internal policing and local governance, while reporting back to a federal authority in Amman — itself restructured to reflect shared governance between the different states. This model may sound unprecedented in the Middle East, but it is not so different from the federal system of the United Arab Emirates or that of the United States. Just as Alaska and Hawaii — non-contiguous and culturally distinct — are integral parts of the American union, so too could a Palestinian West Bank and Gaza remain part of a wider Jordanian federation. Amman would act as the political capital, whilst managing Jerusalem's Islamic holy sites on behalf of all Muslims — a responsibility it already holds with international consent. The Hashemite family would remain the ruling monarchy but the prime minister would be chosen by popular vote by the states. This is almost identical to the United Kingdom, in which the Windsor family are the ruling monarchy but the prime minister is chosen by popular vote by the citizens of England, Scotland, Wales and Northern Island. The benefits could be profound. First, dissent within Jordan would be channeled into structured political representation. Palestinian-Jordanians would no longer be torn between their heritage and their passports — they would be empowered stakeholders in a shared, sovereign future. Second, Palestinians in the West Bank and Gaza would gain credible, experienced governance. Jordan's bureaucracy, civil service and military are among the most respected in the Arab world. Corruption would fall; investor confidence would rise. With Jordanian oversight, Palestinian autonomy would no longer mean instability and isolation. Third, Israel would gain a reliable partner on its eastern and southern borders — one that has a proven record of rejecting terrorism, maintaining peace agreements, and safeguarding regional stability. This would allow Israel to manage its borders securely while supporting genuine Palestinian self-rule under a legitimate and moderate umbrella. Finally, the broader region and the West — especially the United States — would benefit from an end to one of the world's most polarizing and destabilizing conflicts. Domestic political pressures would ease. Radical groups would lose their most powerful propaganda tool. And a long-elusive dream — a real solution for the Palestinians — would finally emerge. Of course, such a vision would require bold diplomacy, careful constitutional design, and broad popular buy-in from Palestinians, Jordanians and Israelis alike. But the alternative — endless stalemate, fractured governance and cycles of violence — is far worse. A century after the fall of Ottoman rule, the time has come for an old-new vision of federal statehood — one rooted not in slogans or fantasies but in history, practicality and hope. Terry Newman is an entrepreneur and investor who works throughout the Middle East. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
